Carisma Therapeutics
CARM

$0.9800

0.06%

Market Cap: $40.7M

About: CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.

Employees: 68

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,728 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

2% more funds holding

Funds holding: 51 [Q1] → 52 (+1) [Q2]

5% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 20

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

6.55% less ownership

Funds ownership: 21.25% [Q1] → 14.69% (-6.55%) [Q2]

52% less capital invested

Capital invested by funds: $19.5M [Q1] → $9.28M (-$10.2M) [Q2]

65% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 17

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$8

716%

upside

Avg. target

$8

716%

upside

High target

$8

716%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Mitchell Kapoor 48% 1-year accuracy 59 / 124 met price target	716%upside $8	Buy Reiterated	28 Jun 2024
HC Wainwright & Co. Mitchell Kapoor 48% 1-year accuracy 59 / 124 met price target	716%upside $8	Buy Reiterated	26 Jun 2024

See Analyst Rankings

Financial journalist opinion

Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases

Building on successful pre-clinical in vivo CAR-M data in oncology, the companies will develop in vivo CAR-M for autoimmune diseases Moderna nominated two autoimmune disease targets under the collaboration Carisma is eligible to receive milestones and royalty payments PHILADELPHIA , Sept. 10, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the expansion of its in vivo chimeric antigen receptor macrophage and monocyte (together, "CAR-M") collaboration with Moderna, Inc. (Nasdaq: MRNA) to include the nomination of two targets for the treatment of autoimmune diseases.

Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases

Carisma Therapeutics to Present at Upcoming Conferences

PHILADELPHIA , Sept. 3, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly, President and Chief Executive Officer, will participate in the following upcoming conferences: Baird 2024 Global Healthcare Conference Tuesday, September 10 at 12:50 PM ET New York, NY H.C.

Carisma Therapeutics to Present at Upcoming Conferences

Zacks Investment Research

CARISMA THERAP (CARM) Upgraded to Buy: What Does It Mean for the Stock?

CARISMA THERAP (CARM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

CARISMA THERAP (CARM) Upgraded to Buy: What Does It Mean for the Stock?

Zacks Investment Research

Carisma Therapeutics Inc. (CARM) Reports Q2 Loss, Tops Revenue Estimates

Carisma Therapeutics Inc. (CARM) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.49 per share a year ago.

Carisma Therapeutics Inc. (CARM) Reports Q2 Loss, Tops Revenue Estimates

Carisma Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Initial data for CT-0525, lead product candidate for anti-HER2 program, expected by year-end 2024 Nomination of a development candidate for liver fibrosis program expected in the first quarter of 2025 Nominated first in vivo CAR-M development candidate targeting Glypican-3 to treat hepatocellular carcinoma under the Moderna Collaboration in the second quarter of 2024 Cash and cash equivalents of $40.4 million and $2.0 million received in July under the Moderna Collaboration expected to fund the Company into the third quarter of 2025 PHILADELPHIA , Aug. 8, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the quarter ended June 30, 2024, and highlighted recent business updates. "We've achieved considerable clinical and research advancements this year, and I'm excited about our strong momentum and clear focus for the next 12 months," said Steven Kelly, President and Chief Executive Officer of Carisma.

Carisma Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Carisma Therapeutics Announces Upcoming Presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024

PHILADELPHIA , Aug. 6, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced its upcoming poster presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024, taking place in San Diego, California, November 15 – 19, 2024. Details on the poster presentation at AASLD 2024 are below: Title: Engineered Macrophages Expressing Fibrosis-Modifying Transgenes Ameliorate Liver Fibrosis in Preclinical Models Session Title: MASLD/MASH - Therapeutics: New Agents Publication Number: 3214 Session Date & Time: 11/17/2024, 8:00 am - 5:00 pm The poster presented at AASLD 2024 will be available online in the "Publications" section of Carisma's website at https://carismatx.com/technology/publications/ following the start of the poster session.

Carisma Therapeutics Announces Upcoming Presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024

Carisma Therapeutics Announces Expansion of Its Scientific Advisory Board

Company appoints renowned key opinion leaders in liver fibrosis, Scott Friedman, MD, and Ira Tabas, MD, PhD PHILADELPHIA , Aug. 6, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Dr. Scott Friedman and Dr. Ira Tabas to its Scientific Advisory Board (SAB). Dr. Friedman and Dr. Tabas bring extensive expertise and pioneering contributions in liver fibrosis, which will be instrumental as Carisma continues its program to develop transformative treatments for patients.

Carisma Therapeutics Announces Expansion of Its Scientific Advisory Board

Carisma Therapeutics Announces Changes to its Board of Directors

Appointment of David Scadden, M.D. and Marella Thorell Resignation of Regina Hodits and Björn Odlander PHILADELPHIA , July 1, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Marella Thorell and David Scadden, M.D.

Carisma Therapeutics Announces Changes to its Board of Directors

Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna

Development Candidate targets Glypican-3 for the treatment of solid tumors, including hepatocellular carcinoma Nomination triggers a $2 million milestone payment to Carisma PHILADELPHIA , June 27, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the nomination of the first development candidate ("Development Candidate"), under its collaboration with Moderna, Inc. The Development Candidate is an in vivo CAR-M targeting Glypican-3 ("GPC3") and is designed to treat solid tumors, including hepatocellular carcinoma ("HCC"), the most prevalent type of liver cancer and the fastest-rising cause of cancer-related death in the U.S. This nomination triggers a $2 million milestone payment to Carisma. The nomination of this Development Candidate leverages Carisma's expertise in engineering chimeric antigen receptor monocytes and macrophages ("CAR-M") with Moderna's mRNA and lipid nanoparticle platform to create a novel in vivo cell therapy for oncology.

Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna

Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors

Fast Track designation highlights potential for CT-0525 to address unmet need for patients with solid tumors Initial Phase 1 data expected by year-end 2024 PHILADELPHIA , June 25, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for CT-0525, an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). The FDA's Fast Track program is aimed to facilitate the development, and expedite the review, of novel potential therapies that are designed to treat serious conditions and have the potential to address significant unmet medical need.

Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors

See News Rankings